Romo, Ana http://orcid.org/0000-0003-1081-8191
Rodríguez, Tania Melina
Yu, Guo
Dewey, Ricardo Alfredo http://orcid.org/0000-0003-1677-2745
Funding for this research was provided by:
Consejo Nacional de Investigaciones Científicas y Técnicas (PIP 2013 GI, 11220120100202CO, PIP 2017 528 GI, 11220170100573CO)
Ministry of Science, Technology and Productive Innovation, Argentina | Agencia Nacional de Promoción Científica y Tecnológica (PICT-2020-SERIE A-03635)
Fundación Florencio Fiorini
Article History
Received: 13 June 2023
Revised: 16 October 2023
Accepted: 7 November 2023
First Online: 22 November 2023
Competing interests
: TMR and RAD are co-inventors of the patent family “Isoform of the TGF-beta receptor II”, US10233227B2 (granted in the USA), EP3082846B1 (granted by the European Patent Office), ES2749615T3 (granted in Spain), and AR098827A1 (pending in Argentina). AR, TMR, and RAD are co-inventors on the patent application, “TGF-receptor II isoform, fusion peptide, methods of treatment, and methods in vitro,” US11072647B2 (granted in the United States) and pending in China (CN111100875A1), Australia (AU2019240609A1), Canada (Act 3.060.686), and Argentina (AR116885A1). Patents are owned by CONICET and Fundación Articular and were licensed to RAD BIO S.A.S. by the intellectual property license agreement 2019-890-APNDIR ♯CONICET. AR has shareholder equity in RAD BIO S.A.S., and RAD is a co-founder, and shareholder of RAD BIO S.A.S.